Biogen said on March 04th Monday it will buy NightStarX for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market. Biogen’s offer of $25.50 per share, represents a premium of 68 percent to Nightstar’s Friday close of $15.16. Gene therapy, an emerging field of biotechnology, uses specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition. London-based gene therapy company Nightstar is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
For further information, see: CNBC (https://www.cnbc.com/2019/03/04/biogen-to-buy-nightstar-therapeutics-in-a-800-million-cash-deal.html)